Developer docs
API playgroundTry for free, no card

Search company profiles

Cytovance Biologics

Full company profile

uuid003ws4a

Namestring
Cytovance Biologics
Legal namestring
Cytovance Biologics, Inc.
Websiteurl
cytovance.com
Company typeenum
Private
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, mammalian cell culture services, microbial fermentation CDMO, monoclonal antibody manufacturing, cGMP biopharmaceutical services
Industry1 code
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics Contract Manufacturing (CDMO)
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1cGMP Contract Manufacturing (Clinical & Commercial)
TypeProfessional Services
Description

Cytovance's primary revenue stream is fee-for-service contract development and manufacturing (CDMO) for biologics, covering both mammalian cell culture and microbial fermentation from preclinical through commercial phases. Revenue is generated on a project-by-project basis, with flexible pricing structures accommodating clients across the spectrum from small biotech to large pharma. The company has supported three commercially approved drug products and 300+ client programs globally.

cytovance.com
2Process Development and Analytical Services
TypeProfessional Services
Description

Cytovance generates revenue from integrated process development, cell line development, strain development, analytical method development, process characterization, and regulatory support services. These are offered as part of the end-to-end CDMO service continuum, bundled with manufacturing or as standalone engagements.

cytovance.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cytovance Biologics is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) that develops and manufactures large-molecule therapeutics—including monoclonal antibodies, fusion proteins, enzymes, vaccines, and recombinant proteins—from both mammalian cell culture (CHO) and microbial fermentation (E. coli and yeast). The company offers end-to-end services spanning strain and cell line development, upstream and downstream process development, analytical development, cGMP manufacturing (up to 2,000L single-use bioreactors and 1,000L microbial fermenters), fill-finish, regulatory support, and global logistics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 84 proteins successfully expressed in microbial systems over the past decade
+5 more records
Product overview1 text field

Cytovance Biologics is a fully integrated biologics CDMO (Contract Development and Manufacturing Organization) offering comprehensive large molecule development and manufacturing services. The portfolio is organized around two primary expression platforms—Microbial CDMO Services and Mammalian CDMO Services—supplemented by CMC Services, CDMO Support Services, and proprietary technology. Microbial services leverage E.coli and yeast systems via the proprietary Keystone™ Expression System, while mammalian services utilize CHO cell platforms including the ThermoFisher Freedom™ CHO-S system. The integrated offering spans the full product lifecycle from DNA to IND submission through commercial manufacturing, with capabilities including strain/cell line development, process development, analytical development, cGMP manufacturing, regulatory support, and global logistics. Recent additions include in-house cell line development (June 2026) and formulation development (September 2025) that complete the end-to-end service continuum.

Product and service8 records
1Microbial CDMO Services
CategoryMicrobial Biologics Manufacturing
Description

End-to-end microbial-derived biologics development and manufacturing services, including strain development using E. coli and yeast (Pichia pastoris, Saccharomyces cerevisiae), process development, analytical development, and cGMP manufacturing with up to 1,000L capacity. Targeted at biotech and pharma clients developing microbial-expressed proteins, enzymes, and other biologics.

2Mammalian CDMO Services
CategoryMammalian Biologics Manufacturing
Description

Mammalian cell culture services from cell line development to commercial manufacturing of monoclonal antibodies, fusion proteins, bispecifics, TriKEs, cytokines, and enzymes using CHO cells with up to 2,000L single-use bioreactor capacity. Targeted at developers of complex mammalian-expressed biologics.

3CMC Services
CategoryCMC and Regulatory Services
Description

Chemistry, Manufacturing, and Controls services including regulatory affairs guidance, process characterization using Quality by Design (QbD) approaches, and process validation supporting product commercialization. Targeted at biologic developers seeking CMC and regulatory support across pre-IND through commercial phases.

4CDMO Support Services
CategoryCDMO Support Services
Description

Comprehensive CDMO support services including global logistics, stability testing, and analytical and microbial testing for drug substance and drug product release. Targeted at biologics developers needing end-to-end release and distribution support.

5Fill-Finish Services
CategoryAseptic Fill-Finish Services
Description

Early-phase vial filling and labeling services for preclinical and Phase 1 drug products, supported by semi-automated pumps and a 1,200-batch vial filling capacity. Targeted at biotech clients preparing clinical trial material.

6Keystone Expression System
CategoryMicrobial Expression Platform
Description

Proprietary E. coli expression platform offering royalty-free control over the manufacturing process by simultaneously evaluating multiple strains in scaled-down batch and fed-batch formats, enabling high-productivity microbial production for biologic developers.

7In-House Cell Line Development Services
CategoryMammalian Cell Line Development
Description

Launched in June 2026, an in-house mammalian cell line development service that generates stable, high-producing CHO cell lines with headline titers reaching up to 10 g/L for monoclonal antibodies, providing an integrated path from DNA to IND submission for biologic developers.

8In-House Formulation Development Services
CategoryFormulation Development
Description

Launched in September 2025, in-house formulation development services grounded in Quality by Design (QbD) principles, delivering speed, safety, and data-driven precision to biologic drug developers as part of Cytovance's end-to-end CDMO offering.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Cytovance entered into a development and manufacturing agreement with Anixa Biosciences for the cGMP manufacture of clinical materials to support its planned Phase 2 clinical trial of its breast cancer vaccine. The vaccine, developed in collaboration with Cleveland Clinic, targets alpha-lactalbumin. Phase 1 results demonstrated safety, tolerability at maximum tolerated dose, and immune responses in 74% of participants. Cytovance's expertise in cGMP biologics production provides the technical strength and reliability necessary for the Phase 2 development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-08
Description

Cytovance partnered with ExcellGene SA to provide cutting-edge options for mammalian-expressed products. This partnership offers the industry integrated solutions for mammalian-expressed large molecule biologics, combining ExcellGene's expression platform expertise with Cytovance's manufacturing capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-02
Description

Cytovance partnered with Celltheon to offer a complete, U.S.-based platform solution for mAbs and difficult-to-express proteins. This partnership provides an integrated solution for customers seeking to outsource cell line development through to cGMP manufacturing, leveraging Celltheon's platform expertise with Cytovance's manufacturing capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-28
Description

Cytovance partnered with Vectron Biosolutions for custom microbial strain development using Vectron's proprietary expression and secretion technologies. The partnership leverages Vectron's expertise in E. coli-based expression and secretion technologies to custom-engineer vectors for maximal titers of biologically active proteins, achieving secreted titers in the g/L scale. The collaboration utilizes Vectron's VB Secretion technology to direct transport of proteins out of the cell, preventing insoluble aggregate accumulation and enabling significant downstream purification resource reductions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-11
Description

Cytovance announced a strategic collaboration with Alcami Corporation to expand large molecule biologic manufacturing and sterile fill-finish offerings. The partnership combines Cytovance's bulk drug substance development and manufacturing services with Alcami's expertise in liquid and lyophilization sterile filling, packaging, labeling, formulation, release, and stability testing. This best-of-breed partnership expedites sterile injectables to patients through optimized transfer of bulk drug substance to finished drug product. The two companies are coordinating manufacturing processes and quality systems.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

Cytovance and PolyPeptide announced a collaboration to offer integrated peptide production for microbial and mammalian-expressed peptide drugs. This collaboration provides an integrated solution for customers seeking to outsource the development and manufacturing of peptide therapeutics.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-22
Description

Cytovance partnered with Phenotypeca to enhance Saccharomyces cerevisiae strain development for microbial biomanufacturing. The partnership leverages Phenotypeca's proprietary QTL (Quantitative Trait Loci) technology, which integrates breeding methods with genomic-based screening to fine-tune yeast strains for specific proteins. This enables multi-parameter optimization for premium recombinant protein manufacturing processes, generating and screening billions of progeny strains to identify top performers.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large-scale biologics CDMO with microbial and mammalian capabilities, including cGMP manufacturing and process development. Broad incumbent with overlapping service portfolio but significantly larger capacity and global footprint than Cytovance.

TypeBroad incumbent
Description

World's largest CDMO with comprehensive biologics (mammalian and microbial) and small molecule services across global mega-scale facilities. Comparable as a broad incumbent in biologics CDMO with overlapping expression platforms but vastly larger scale; Cytovance CCO held leadership roles at Lonza.

TypeBroad incumbent
Description

One of the world's largest contract biologics manufacturers with multi-10,000L bioreactor capacity serving global pharma and biotech. Broad incumbent offering overlapping mammalian CDMO services but at a dramatically larger scale than Cytovance.

TypeDirect peer
Description

Global CDMO offering mammalian and microbial biologics development and manufacturing across multiple sites. Directly comparable as a mid-to-large biologics CDMO serving similar biotech and pharma clients with overlapping expression platforms; Cytovance CCO Axel Schleyer previously held leadership roles there.

TypeDirect peer
Description

Bioprocess CDMO offering microbial, mammalian, and fill-finish services to global clients. Comparable as a mid-sized biologics CDMO with similar business model; Cytovance CCO Axel Schleyer was previously SVP of Business Development at Stelis.

TypeDirect peer
Description

Contract development and manufacturing organization specializing in microbial and mammalian biologics. Comparable as a mid-sized biologics CDMO with similar expression platform breadth; Cytovance Sr. Director of Manufacturing Brent Van Rite previously held manufacturing leadership there.

TypeDirect peer
Description

Canadian CDMO specializing in biologics (microbial fermentation and mammalian cell culture) and small molecule manufacturing. Comparable mid-sized CDMO with dual platform expression capabilities serving biotech and pharma clients.

TypeDirect peer
Description

U.S.-based CDMO providing biologics and small molecule manufacturing including sterile fill-finish. Directly comparable as a strategic partner and peer CDMO; Cytovance and Alcami have a formal collaboration combining bulk drug substance (Cytovance) with fill-finish (Alcami).

9Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Global biologics CDMO operated by Boehringer Ingelheim, providing mammalian cell culture and microbial contract manufacturing at commercial scale. Broad incumbent with similar mammalian/microbial focus but vastly greater scale; Cytovance CCO and R&D Director previously held roles there.

TypeDirect peer
Description

Biologics CDMO and contract research services provider with mammalian and microbial capabilities. Directly comparable as a mid-sized CDMO with overlapping services; Cytovance CCO Axel Schleyer was previously President and CEO, and Sr. Director Brent Van Rite also held manufacturing roles there.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cytovance Biologics

Biologics Contract Manufacturing (CDMO)cytovance.com

Cytovance Biologics firmographics

Firmographics
Name
Cytovance Biologics
Legal name
Cytovance Biologics, Inc.
Website
https://cytovance.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Cytovance Biologics industry classification

Industry
Product category
Biologics Contract Manufacturing (CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics contract manufacturing
  • Mammalian cell culture services
  • Microbial fermentation CDMO
  • Monoclonal antibody manufacturing
  • CGMP biopharmaceutical services

Where Cytovance Biologics is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cytovance Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. cGMP Contract Manufacturing (Clinical & Commercial): Cytovance's primary revenue stream is fee-for-service contract development and manufacturing (CDMO) for biologics, covering both mammalian cell culture and microbial fermentation from preclinical through commercial phases. Revenue is generated on a project-by-project basis, with flexible pricing structures accommodating clients across the spectrum from small biotech to large pharma. The company has supported three commercially approved drug products and 300+ client programs globally.
  2. Process Development and Analytical Services: Cytovance generates revenue from integrated process development, cell line development, strain development, analytical method development, process characterization, and regulatory support services. These are offered as part of the end-to-end CDMO service continuum, bundled with manufacturing or as standalone engagements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Cytovance Biologics product offering

Product offering

Core offering

Cytovance Biologics is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) that develops and manufactures large-molecule therapeutics—including monoclonal antibodies, fusion proteins, enzymes, vaccines, and recombinant proteins—from both mammalian cell culture (CHO) and microbial fermentation (E. coli and yeast). The company offers end-to-end services spanning strain and cell line development, upstream and downstream process development, analytical development, cGMP manufacturing (up to 2,000L single-use bioreactors and 1,000L microbial fermenters), fill-finish, regulatory support, and global logistics.

Product overview

Cytovance Biologics is a fully integrated biologics CDMO (Contract Development and Manufacturing Organization) offering comprehensive large molecule development and manufacturing services. The portfolio is organized around two primary expression platforms—Microbial CDMO Services and Mammalian CDMO Services—supplemented by CMC Services, CDMO Support Services, and proprietary technology. Microbial services leverage E.coli and yeast systems via the proprietary Keystone™ Expression System, while mammalian services utilize CHO cell platforms including the ThermoFisher Freedom™ CHO-S system. The integrated offering spans the full product lifecycle from DNA to IND submission through commercial manufacturing, with capabilities including strain/cell line development, process development, analytical development, cGMP manufacturing, regulatory support, and global logistics. Recent additions include in-house cell line development (June 2026) and formulation development (September 2025) that complete the end-to-end service continuum.

Differentiator

Problem solved

Functional benefit

Products and services

  • Microbial CDMO Services End-to-end microbial-derived biologics development and manufacturing services, including strain development using E. coli and yeast (Pichia pastoris, Saccharomyces cerevisiae), process development, analytical development, and cGMP manufacturing with up to 1,000L capacity. Targeted at biotech and pharma clients developing microbial-expressed proteins, enzymes, and other biologics.
  • Mammalian CDMO Services Mammalian cell culture services from cell line development to commercial manufacturing of monoclonal antibodies, fusion proteins, bispecifics, TriKEs, cytokines, and enzymes using CHO cells with up to 2,000L single-use bioreactor capacity. Targeted at developers of complex mammalian-expressed biologics.
  • CMC Services Chemistry, Manufacturing, and Controls services including regulatory affairs guidance, process characterization using Quality by Design (QbD) approaches, and process validation supporting product commercialization. Targeted at biologic developers seeking CMC and regulatory support across pre-IND through commercial phases.
  • CDMO Support Services Comprehensive CDMO support services including global logistics, stability testing, and analytical and microbial testing for drug substance and drug product release. Targeted at biologics developers needing end-to-end release and distribution support.
  • Fill-Finish Services Early-phase vial filling and labeling services for preclinical and Phase 1 drug products, supported by semi-automated pumps and a 1,200-batch vial filling capacity. Targeted at biotech clients preparing clinical trial material.
  • Keystone Expression System Proprietary E. coli expression platform offering royalty-free control over the manufacturing process by simultaneously evaluating multiple strains in scaled-down batch and fed-batch formats, enabling high-productivity microbial production for biologic developers.
  • In-House Cell Line Development Services Launched in June 2026, an in-house mammalian cell line development service that generates stable, high-producing CHO cell lines with headline titers reaching up to 10 g/L for monoclonal antibodies, providing an integrated path from DNA to IND submission for biologic developers.
  • In-House Formulation Development Services Launched in September 2025, in-house formulation development services grounded in Quality by Design (QbD) principles, delivering speed, safety, and data-driven precision to biologic drug developers as part of Cytovance's end-to-end CDMO offering.

Quantifiable outcome

  • 84 proteins successfully expressed in microbial systems over the past decade
  • +5 more outcomes

Companies that use Cytovance Biologics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Cytovance Biologics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cytovance Biologics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Anixa BiosciencescoreStrategic or Co-development Partner · 1 April 2026Cytovance entered into a development and manufacturing agreement with Anixa Biosciences for the cGMP manufacture of clinical materials to support its planned Phase 2 clinical trial of its breast cancer vaccine. The vaccine, developed in collaboration with Cleveland Clinic, targets alpha-lactalbumin. Phase 1 results demonstrated safety, tolerability at maximum tolerated dose, and immune responses in 74% of participants. Cytovance's expertise in cGMP biologics production provides the technical strength and reliability necessary for the Phase 2 development.
  • ExcellGene SAcoreStrategic or Co-development Partner · 8 May 2024Cytovance partnered with ExcellGene SA to provide cutting-edge options for mammalian-expressed products. This partnership offers the industry integrated solutions for mammalian-expressed large molecule biologics, combining ExcellGene's expression platform expertise with Cytovance's manufacturing capabilities.
  • CelltheoncoreStrategic or Co-development Partner · 2 April 2024Cytovance partnered with Celltheon to offer a complete, U.S.-based platform solution for mAbs and difficult-to-express proteins. This partnership provides an integrated solution for customers seeking to outsource cell line development through to cGMP manufacturing, leveraging Celltheon's platform expertise with Cytovance's manufacturing capabilities.
  • Vectron BiosolutionscoreTechnology or Integration · 28 March 2024Cytovance partnered with Vectron Biosolutions for custom microbial strain development using Vectron's proprietary expression and secretion technologies. The partnership leverages Vectron's expertise in E. coli-based expression and secretion technologies to custom-engineer vectors for maximal titers of biologically active proteins, achieving secreted titers in the g/L scale. The collaboration utilizes Vectron's VB Secretion technology to direct transport of proteins out of the cell, preventing insoluble aggregate accumulation and enabling significant downstream purification resource reductions.
  • AlcamicoreStrategic or Co-development Partner · 11 December 2023Cytovance announced a strategic collaboration with Alcami Corporation to expand large molecule biologic manufacturing and sterile fill-finish offerings. The partnership combines Cytovance's bulk drug substance development and manufacturing services with Alcami's expertise in liquid and lyophilization sterile filling, packaging, labeling, formulation, release, and stability testing. This best-of-breed partnership expedites sterile injectables to patients through optimized transfer of bulk drug substance to finished drug product. The two companies are coordinating manufacturing processes and quality systems.
  • PolyPeptideminorStrategic or Co-development Partner · 19 September 2023Cytovance and PolyPeptide announced a collaboration to offer integrated peptide production for microbial and mammalian-expressed peptide drugs. This collaboration provides an integrated solution for customers seeking to outsource the development and manufacturing of peptide therapeutics.
  • PhenotypecacoreTechnology or Integration · 22 August 2023Cytovance partnered with Phenotypeca to enhance Saccharomyces cerevisiae strain development for microbial biomanufacturing. The partnership leverages Phenotypeca's proprietary QTL (Quantitative Trait Loci) technology, which integrates breeding methods with genomic-based screening to fine-tune yeast strains for specific proteins. This enables multi-parameter optimization for premium recombinant protein manufacturing processes, generating and screening billions of progeny strains to identify top performers.

Scale indicators11 records

Recent moves9 records

Expansion highlights4 records

Cytovance Biologics competitors and assessment

Company assessment

Broad incumbents

  • FUJIFILM Diosynth Biotechnologies: Large-scale biologics CDMO with microbial and mammalian capabilities, including cGMP manufacturing and process development. Broad incumbent with overlapping service portfolio but significantly larger capacity and global footprint than Cytovance.
  • Lonza: World's largest CDMO with comprehensive biologics (mammalian and microbial) and small molecule services across global mega-scale facilities. Comparable as a broad incumbent in biologics CDMO with overlapping expression platforms but vastly larger scale; Cytovance CCO held leadership roles at Lonza.
  • Samsung Biologics: One of the world's largest contract biologics manufacturers with multi-10,000L bioreactor capacity serving global pharma and biotech. Broad incumbent offering overlapping mammalian CDMO services but at a dramatically larger scale than Cytovance.
  • Boehringer Ingelheim BioXcellence: Global biologics CDMO operated by Boehringer Ingelheim, providing mammalian cell culture and microbial contract manufacturing at commercial scale. Broad incumbent with similar mammalian/microbial focus but vastly greater scale; Cytovance CCO and R&D Director previously held roles there.

Direct peers

  • AGC Biologics: Global CDMO offering mammalian and microbial biologics development and manufacturing across multiple sites. Directly comparable as a mid-to-large biologics CDMO serving similar biotech and pharma clients with overlapping expression platforms; Cytovance CCO Axel Schleyer previously held leadership roles there.
  • Stelis BioPharma: Bioprocess CDMO offering microbial, mammalian, and fill-finish services to global clients. Comparable as a mid-sized biologics CDMO with similar business model; Cytovance CCO Axel Schleyer was previously SVP of Business Development at Stelis.
  • Northway Biotech: Contract development and manufacturing organization specializing in microbial and mammalian biologics. Comparable as a mid-sized biologics CDMO with similar expression platform breadth; Cytovance Sr. Director of Manufacturing Brent Van Rite previously held manufacturing leadership there.
  • BioVectra: Canadian CDMO specializing in biologics (microbial fermentation and mammalian cell culture) and small molecule manufacturing. Comparable mid-sized CDMO with dual platform expression capabilities serving biotech and pharma clients.
  • Alcami Corporation: U.S.-based CDMO providing biologics and small molecule manufacturing including sterile fill-finish. Directly comparable as a strategic partner and peer CDMO; Cytovance and Alcami have a formal collaboration combining bulk drug substance (Cytovance) with fill-finish (Alcami).
  • Aragen Bioscience: Biologics CDMO and contract research services provider with mammalian and microbial capabilities. Directly comparable as a mid-sized CDMO with overlapping services; Cytovance CCO Axel Schleyer was previously President and CEO, and Sr. Director Brent Van Rite also held manufacturing roles there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cytovance Biologics social profiles

Digital presence

Cytovance Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cytovance Biologics leadership team

Management profile

Number of profiles

Profiles7 records

Cytovance Biologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cytovance Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytovance Biologics

What does Cytovance Biologics do?

Cytovance Biologics is a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) that develops and manufactures large-molecule therapeutics—including monoclonal antibodies, fusion proteins, enzymes, vaccines, and recombinant proteins—from both mammalian cell culture (CHO) and microbial fermentation (E. coli and yeast). The company offers end-to-end services spanning strain and cell line development, upstream and downstream process development, analytical development, cGMP manufacturing (up to 2,000L single-use bioreactors and 1,000L microbial fermenters), fill-finish, regulatory support, and global logistics.

Is Cytovance Biologics a public or private company?

Cytovance Biologics is a private company. It is classified as private equity controlled and is currently operating.

When was Cytovance Biologics founded?

Cytovance Biologics was founded in 2005. It employs 101 to 250 people.

Where is Cytovance Biologics based?

Cytovance Biologics is headquartered in Oklahoma City, United States, in the North America region.

How does Cytovance Biologics make money?

Two revenue lines are on record. cGMP Contract Manufacturing (Clinical & Commercial) is the primary driver. The others are process Development and Analytical Services.

Who are Cytovance Biologics's main competitors?

Broad incumbents on record are FUJIFILM Diosynth Biotechnologies, Lonza, Samsung Biologics and Boehringer Ingelheim BioXcellence. Direct peers are AGC Biologics, Stelis BioPharma, Northway Biotech, BioVectra, Alcami Corporation and Aragen Bioscience.

Does Cytovance Biologics have an API?

No public API is recorded for Cytovance Biologics.

What industry is Cytovance Biologics in?

Cytovance Biologics's product category is Biologics Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TalkMarketsCytovance Biologics Expands Standalone Analytical Services for Biopharmaceutical ClientsCytovance Biologics announced the expansion of its portfolio to offer standalone analytical services, allowing biopharmaceutical clients to access specialized laboratory testing without committing to broader manufacturing contracts. This unbundled approach enables drug developers to utilize the company's scientific expertise and regulatory-ready frameworks for tasks such as method development, validation, and stability studies while preserving operational agility.BioSpaceCytovance Biologics Launches Standalone Analytical Services to Accelerate Biologics DevelopmentCytovance Biologics announced standalone analytical services for biopharma clients, offering GMP and non-GMP testing without manufacturing engagement. The services cover method development, validation, product characterization, and stability studies, aiming to support biologics development from early-stage to commercialization.Business Wire BlogCytovance Biologics Expands Process Development Services with Perfusion CapabilitiesCytovance Biologics, a US-based contract development and manufacturing organization (CDMO), announced the expansion of its upstream process development services with new perfusion capabilities for biopharmaceutical manufacturing. The perfusion technology allows continuous replenishment of fresh media while removing spent media, enabling longer cell culture durations and improved productivity compared to traditional fed-batch processes. This investment builds on Cytovance's recent expansions of cell line development and formulation development services, strengthening its integrated CDMO offering.Investing.comH.C. Wainwright reiterates Buy on Anixa stock, $7 target By Investing.comH.C. Wainwright reaffirmed its Buy rating and $7.00 price target on Anixa Biosciences following the company's fiscal second-quarter results for the quarter ending April 30, 2026, during which Anixa reported a net loss of $2.5 million and negative operating cash flows of $1.7 million, while maintaining $13.7 million in cash and a strong balance sheet with a current ratio of 9.79. The company also released updated survival data from its ongoing Phase 1 trial of liraltagene autoleucel, a CAR-T therapy for recurrent ovarian cancer, showing that trial participants have significantly exceeded expected median survival of three to four months, with one patient surviving 28 months. Additional developments include patent approvals in Canada and Mexico for Anixa's cancer vaccine technologies and progress toward a Phase 2 trial of its breast cancer vaccine with partner Cytovance Biologics.ContractpharmaCytovance Biologics Adds Cell Line Development ServicesCytovance Biologics, a U.S.-based contract development and manufacturing organization (CDMO), has expanded its mammalian cell culture capabilities with the addition of in-house cell line development services, building on its recent launch of formulation development capabilities to provide an integrated offering from DNA to IND submission. The company enters the cell line development market with headline titers reaching up to 10 g/L for monoclonal antibodies, positioning it as a leading performer in CHO expression systems that can reduce manufacturing costs and accelerate timelines for clients. CEO Ping Zhang stated the expansion helps clients move from concept to clinic by eliminating external handoffs and providing a more efficient, data-driven development path.BioSpaceCytovance Biologics Launches In-House Cell Line Development with High-Yield Titers up to 10g/LCytovance Biologics launched in-house cell line development services, adding to its CDMO offerings. The platform achieves titers up to 10 g/L for monoclonal antibodies, aiming to speed process development and reduce costs. The company says this integrates its services from DNA to IND submission.PharmiWeb.comPlasmid DNA Manufacturing Market Report 2025-2035, with Profiles of AGC Biologics, Aldevron, Biomay, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, VGXI, and More - ResearchAndThe global plasmid DNA manufacturing market is projected to grow from USD 0.1 billion in 2025 to USD 0.53 billion by 2035, a CAGR of 14.85%. Growth is driven by cell and gene therapy development, with over 70 service providers and more than 50% offering GMP-grade services.Business Wire BlogCDMO Cytovance Biologics and CDO Celltheon Partner to Offer a Complete, US-based Platform Solution for mAbs and Difficult-to-Express ProteinsCytovance Biologics and Celltheon partnered to offer an integrated platform for monoclonal antibody and difficult-to-express protein production. The arrangement combines Celltheon's CHO-K1 cell line development with Cytovance's cGMP manufacturing, including 1000L and 2000L bioreactors. The collaboration aims to expand customer options for cell line selection and accelerate time to market.ContractpharmaExcellGene, Cytovance Partner to Advance Biologics Development and ManufactureExcellGene SA and Cytovance Biologics announced a partnership to combine ExcellGene's transposon-engineered CHO and HEK cell lines with Cytovance's cGMP manufacturing. The collaboration aims to deliver protein yields up to 10 g/L, supporting customers' therapeutics from development to commercial scale.GlobeNewswireCytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial BiomanufacturingCytovance Biologics and Phenotypeca entered an agreement to provide optimized Saccharomyces cerevisiae strains for biopharmaceutical manufacturing. The collaboration aims to accelerate yeast strain development and improve biologics production efficiency, leveraging Cytovance's fermentation expertise and Phenotypeca's yeast technology.